SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Carvana Co. is a holding company and an eCommerce platform, which engages in the buying and selling of used cars. The company was founded by Ernest Garcia, III, Benjamin Huston and Ryan Keeton in 2012 and is headquartered in Tempe, AZ.

Carvana Co. - Ordinary Shares - Class A

Carvana Co.

Carvana is trending after its Q4 earnings report presented mixed signals with a large EPS beat but misses on key profit metrics and vague guidance, sparking extreme price volatility and an intense community debate. Many investors are questioning the stock's valuation and rapid pre-market rebound, alleging manipulation and "scam" tactics amidst concerns over accounting quality and related-party dealings.

Figma, Inc. is an AI-powered design platform that enables seamless collaboration across the entire product development lifecycle. Its products include FigJam, Figma Slides, Figma Design, Figma Draw, Dev Mode, Figma Sites, Figma Buzz and Figma Make. The company was founded by Dylan Joseph Field and Evan Darrow Wallace in 2012 and is headquartered in San Francisco, CA.

Figma Inc. - Ordinary Shares - Class A

Figma

Figma (FIG) is experiencing extreme volatility after reporting a strong Q4 earnings beat and optimistic 2026 guidance, including accelerating AI monetization, though initial gains quickly faded. The community is actively debating potential market manipulation and recent analyst downgrades, with many pointing to an inverse Cramer effect and significant institutional buying amidst the ongoing 'SAASpocalypse' narrative.

Klarna Group Plc is a global digital bank and flexible payments provider. It operates through an AI-powered payments and commerce network that empowers people to pay smarter, with a mission to be available everywhere, for everything. The company was founded by Gustav Erik Niklas Adalberth, Karl Anders Victor Jacobsson, and Sebastian Marcin Siemiatkowski in 2005 and is headquartered in London, the United Kingdom.

Klarna Group plc

Klarna Group plc is trending after reporting strong revenue growth but a net loss driven by credit loss provisions, fueling mixed community sentiment about its immediate prospects and long-term viability within the fintech sector. The market is also actively debating how a proposed cap on credit card interest rates could significantly benefit Klarna's merchant-funded buy-now-pay-later model by shifting consumer behavior.

Walmart, Inc. engages in the retail and wholesale business. The company offers an assortment of merchandise and services at everyday low prices. It operates through the following business segments: Walmart U.S., Walmart International, and Sam's Club. The Walmart U.S. segment operates as a mass merchandiser of consumer products, operating under the Walmart and Walmart Neighborhood Market brands, including walmart.com. The Walmart International segment includes operations of wholly-owned subsidiaries in Canada, Chile, China, and Africa, and majority-owned subsidiaries in India, as well as Mexico and Central America. The Sam's Club segment manages membership-only warehouse clubs and operates samsclub.com. The company was founded by Samuel Moore Walton and James Lawrence Walton on July 2, 1962 and is headquartered in Bentonville, AR.

Walmart Inc

Walmart is trending following its Q4 earnings report, which highlighted strong e-commerce growth and a significant new share repurchase program. Despite these positives, cautious forward guidance is intensifying community discussion around the stock's elevated valuation within the retail sector.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is a top trending stock after securing conditional EU marketing authorization for its bladder cancer therapy, ANKTIVA, and announcing a European distribution partnership, fueling widespread investor debate over a potential short squeeze due to high short interest and the company's ambitious global expansion strategy.

DoorDash, Inc. engages in the design, development, and operation of a food delivery and logistics platform. It serves consumers in the United States, Canada, and Australia. The company was founded by Andy Fang, Tony Xu, Stanley Tang, and Evan Moore on January 12, 2013 and is headquartered in San Francisco, CA.

DoorDash Inc - Ordinary Shares - Class A

DoorDash is trending as shares surged following its latest earnings report, which, despite mixed financials, highlighted strong Gross Order Volume and strategic investments in growth and AI partnerships. However, community sentiment remains split, with some celebrating its long-term potential and insider confidence, while others question its high valuation and the sustainability of consumer demand amidst broader economic pressures and regulatory scrutiny.

Lemonade, Inc. is a holding company, which engages in the provision of insurance services. The firm's products include renters and homeowners insurance, and pet insurance. It offers insurance coverage under the homeowners multi-peril, inland marine, and general liability lines of business. The company was founded by Daniel Asher Schreiber and Shai Wininger on June 17, 2015 and is headquartered in New York, NY.

Lemonade Inc

Lemonade Inc. is trending after exceeding Q4 earnings expectations and providing strong guidance, which initially ignited a rally and short squeeze. This was further amplified by news of its 50% insurance discount for Tesla FSD users, though community discussion now centers on the stock's sharp post-earnings reversal and future valuation.

Medical Properties Trust, Inc. is a self-advised real estate investment trust. It engages in the investment, acquisition, and development of net-leased healthcare facilities. Its property portfolio includes rehabilitation hospitals, long-term acute care hospitals, ambulatory surgery centers, hospitals for women and children, regional and community hospitals, medical office buildings, and other single-discipline facilities. The company was founded by Edward K. Aldag Jr., R. Steven Hamner, Emmett E. McLean, and William Gilliard McKenzie in 2003 and is headquartered in Birmingham, AL.

Medical Properties Trust Inc

Medical Properties Trust is actively discussed following a positive earnings report and share buyback updates, leading to strong community sentiment that a significant short squeeze is imminent for the undervalued healthcare REIT as a turnaround gains momentum.

Booking Holdings, Inc. engages in the provision of online travel and related solutions. The firm offers services through the following brands: Booking.com, Priceline, Agoda, KAYAK, and OpenTable. It provides accommodation reservations including hotels, hostels, apartments, vacation rentals, and other properties. The company was founded by Jay Scott Walker on July 18, 1997, and is headquartered in Norwalk, CT.

Booking Holdings Inc

Booking Holdings is trending after reporting strong Q4 earnings, providing robust guidance, and announcing a 25-to-1 stock split effective in 2026, alongside a dividend increase and an AI push. The community is largely bullish on these results and future prospects in the travel sector, although some express skepticism regarding the long-term implications of stock splits and potential AI-driven disruption.

Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca A. Taub, Frederick Bernard Craves, and Edward Chiang on March 10, 2000 and is headquartered in West Conshohocken, PA.

Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals is trending following strong sales of its MASH drug Rezdiffra, which outperformed revenue estimates, yet a notable earnings per share loss due to aggressive pipeline expansion and operating expenses is fueling investor debate. The community is weighing management's long-term growth strategy against concerns about profitability and active speculation of a potential buyout.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$COGT Cogent Biosciences reports Q4 net loss $102.5M vs. $67.9M last year 
 
&quot;Following three positive pivotal trials in 2025, we have entered 2026 with tremendous momentum and multiple value-creating regulatory catalysts underway,&quot; said Andrew Robbins, Cogent&#39;s President and Chief Executive Officer. &quot;We have submitted our SUMMIT NDA for bezuclastinib in patients with NonAdvSM, initiated our PEAK NDA under the FDA&#39;s RTOR program for bezuclastinib in patients with second-line GIST, and remain on track to submit our APEX NDA for bezuclastinib in patients with AdvSM in the first half of this year. These recent and upcoming milestones underscore the breadth of bezuclastinib&#39;s best-in-class potential across KIT-mutant driven diseases. With a very strong balance sheet entering 2026, we will soon finish building our commercial organization and will be ready to launch bezuclastinib in the second half of 2026.&quot;

StockTwits Web

Cogent Biosciences Inc

 Cogent Biosciences reports Q4 net loss $102.5M vs. $67.9M last year 
 
"Following three positive pivotal trials in 2025, we have entered 2026 with tremendous momentum and multiple value-creating regulatory catalysts underway," said Andrew Robbins, Cogent's President and Chief Executive Officer. "We have submitted our SUMMIT NDA for bezuclastinib in patients with NonAdvSM, initiated our PEAK NDA under the FDA's RTOR program for bezuclastinib in patients with second-line GIST, and remain on track to submit our APEX NDA for bezuclastinib in patients with AdvSM in the first half of this year. These recent and upcoming milestones underscore the breadth of bezuclastinib's best-in-class potential across KIT-mutant driven diseases. With a very strong balance sheet entering 2026, we will soon finish building our commercial organization and will be ready to launch bezuclastinib in the second half of 2026."